Literature DB >> 22913831

A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries.

D Noone1, B O'Mahony, J P van Dijk, L Prihodova.   

Abstract

A number of studies have been published on the benefits of prophylactic treatment in adults with haemophilia. However, in many countries, it is considered as optional due to financial constraints. This survey was carried out to examine the long-term effects of prophylaxis and the continuing benefit of the treatment into adulthood. Self-assessed health-related data and the EQ-5D questionnaire measuring health utility were collected from 124 men (26.9 ± 4.6 years) from Canada (N = 40), France (N = 14), Ireland (N = 17), the Netherlands (N = 16), Poland (N = 24) and the UK (N = 13). The respondents were split into four groups: On-Demand, <50% life on prophylaxis, ≥ 50% life on prophylaxis, Prophylaxis. Overall, long-term prophylaxis results in lower presence of target joints (P ≤ 0.001), occurrence of serious bleeding episodes (P ≤ 0.05), recurring bleeding episodes (P ≤ 0.01) and requirement for surgical procedures (P ≤ 0.05). Furthermore, health utility (P ≤ 0.01) in the On-demand group was significantly lower (P ≤ 0.01) compared to the ≥ 50% life on prophylaxis and the Prophylaxis group. No significant differences between countries were found except between the Netherlands and Poland, with Poland showing the lowest health utility (P ≤ 0.01) and the most problems with mobility (P ≤ 0.05) and pain/discomfort (P ≤ 0.001). The Netherlands showed the highest health utility (0.915) followed by Canada (0.791), Ireland (0.786), UK (0.768), France (0.687) and Poland (0.629). The results demonstrate consistently higher quality of life of individuals who are on long-term prophylactic treatment when compared to on-demand treatment or intermittent prophylaxis and on -demand treatment.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22913831     DOI: 10.1111/j.1365-2516.2012.02934.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  11 in total

Review 1.  Current and evolving features in the clinical management of haemophilia.

Authors:  Antonio Coppola; Massimo Morfini; Ernesto Cimino; Antonella Tufano; Anna M Cerbone; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

Review 2.  Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.

Authors:  Scott D Grosse; Shraddha S Chaugule; Joel W Hay
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-01-14       Impact factor: 2.217

Review 3.  EQ-5D in Central and Eastern Europe: 2000-2015.

Authors:  Fanni Rencz; László Gulácsi; Michael Drummond; Dominik Golicki; Valentina Prevolnik Rupel; Judit Simon; Elly A Stolk; Valentin Brodszky; Petra Baji; Jakub Závada; Guenka Petrova; Alexandru Rotar; Márta Péntek
Journal:  Qual Life Res       Date:  2016-07-29       Impact factor: 4.147

4.  The effects of joint disease, inhibitors and other complications on health-related quality of life among males with severe haemophilia A in the United States.

Authors:  J M Soucie; S D Grosse; A-E-A Siddiqi; V Byams; J Thierry; M M Zack; A Shapiro; N Duncan
Journal:  Haemophilia       Date:  2017-06-02       Impact factor: 4.287

5.  Association of overweight and obesity with the use of self and home-based infusion therapy among haemophilic men.

Authors:  M Ullman; Q C Zhang; D Brown; A Grant; J M Soucie
Journal:  Haemophilia       Date:  2013-11-22       Impact factor: 4.287

6.  Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II).

Authors:  K Kavakli; R Yang; L Rusen; H Beckmann; D Tseneklidou-Stoeter; M Maas Enriquez
Journal:  J Thromb Haemost       Date:  2015-03       Impact factor: 5.824

7.  The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia.

Authors:  M W Skinner; C Chai-Adisaksopha; R Curtis; N Frick; M Nichol; D Noone; B O'Mahony; D Page; J S Stonebraker; A Iorio
Journal:  Pilot Feasibility Stud       Date:  2018-02-27

8.  Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire.

Authors:  Chatree Chai-Adisaksopha; Mark W Skinner; Randall Curtis; Neil Frick; Michael B Nichol; Declan Noone; Brian O'Mahony; David Page; Jeffrey Stonebraker; Lehana Thabane; Mark Crowther; Alfonso Iorio
Journal:  BMJ Open       Date:  2018-08-08       Impact factor: 2.692

9.  Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study.

Authors:  Angela L Forsyth; Michelle Witkop; Angela Lambing; Cesar Garrido; Spencer Dunn; David L Cooper; Diane J Nugent
Journal:  Patient Prefer Adherence       Date:  2015-10-29       Impact factor: 2.711

10.  The impact of extended half-life versus conventional factor product on hemophilia caregiver burden.

Authors:  Carolyn E Schwartz; Victoria E Powell; Jun Su; Jie Zhang; Adi Eldar-Lissai
Journal:  Qual Life Res       Date:  2018-02-01       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.